Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial, PMID: 32259228
Olaratumab, PMID: 31644245
Olaratumab in soft tissue sarcoma - Current status and future perspectives, PMID: 29413687
Olaratumab, PMID: 29999955
Olaratumab in the management of advanced soft tissue sarcoma, PMID: 30032714
Olaratumab: First Global Approval, PMID: 27995580
Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma, PMID: 30588358
Olaratumab for the treatment of soft-tissue sarcoma, PMID: 28745071
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial, PMID: 27291997
Olaratumab for advanced soft tissue sarcoma, PMID: 28447475
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal, PMID: 28914440
Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma, PMID: 28778132
Olaratumab for the treatment of advanced soft tissue sarcoma, PMID: 28862476
Developments in the management of advanced soft-tissue sarcoma - olaratumab in context, PMID: 29497315
Olaratumab for soft tissue sarcoma, PMID: 28691538
Olaratumab for the treatment of soft tissue sarcoma, PMID: 28492292
Olaratumab for STS Disappoints in Phase III, PMID: 30696623
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma, PMID: 29270033
Incidence and Management of Olaratumab Infusion-Related Reactions, PMID: 31268811
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria, PMID: 31620878
Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience, PMID: 31996176
Olaratumab failure in sarcomas: what are the lessons learned?, PMID: 31254941
Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy, PMID: 29263653
Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer, PMID: 28620891
Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas, PMID: 28917265
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors, PMID: 33474828
Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma, PMID: 30353601
Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma, PMID: 30406840
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland, PMID: 32391141
Olaratumab (Lartruvo): An Innovative Treatment for Soft Tissue Sarcoma, PMID: 29719366
Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?, PMID: 31321082
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma, PMID: 31821732
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC, PMID: 28838379
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma, PMID: 33177152
Uterine leiomyosarcoma: A review of the literature and update on management options, PMID: 30244960
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas, PMID: 32235164
Olaratumab's failure in soft tissue sarcoma, PMID: 34349891
Olaratumab in soft-tissue sarcomas, PMID: 27291995
Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α, PMID: 29191969
Phase I study of olaratumab in Japanese patients with advanced solid tumors, PMID: 24816152
First-Line Therapy for Metastatic Soft Tissue Sarcoma, PMID: 30675651
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer, PMID: 30573277
Minimization of olaratumab drug waste using real-world data, PMID: 28461327
Olaratumab (Lartruvo) for soft-tissue sarcoma, PMID: 28787747
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab, PMID: 33147355
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer, PMID: 30591028
Drug Monographs: Olaratumab and Rucaparib, PMID: 28515503
Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?, PMID: 32161464
Advances of systemic treatment for adult soft-tissue sarcoma, PMID: 30173532
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation, PMID: 28209496
From Growth Factors to Structure: PDGF and TGF-β in Granulation Tissue Formation. A Literature Review., PMID:40495632
Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma., PMID:40468683
What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?, PMID:38750399
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer., PMID:38611000
Best Overall Response-Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE., PMID:38536068
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas., PMID:37835565
Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring EWSR1::CREM fusion: clinicopathological series of two cases and literature review., PMID:37829338
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma., PMID:37382656
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients., PMID:37222199
PDGFRα monoclonal antibody: Assessment of toxicity in juvenile mice administered a murine surrogate antibody of olaratumab., PMID:36916488
Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial., PMID:35547106
Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit., PMID:34919008
Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review., PMID:34848441
Olaratumab-induced Biomarker Modulation in Sarcomas-Response., PMID:34607902
Olaratumab-induced Biomarker Modulation in Sarcomas-Letter., PMID:34607901
Olaratumab's failure in soft tissue sarcoma., PMID:34349891
Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review., PMID:34094927
Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma., PMID:33766818
Modern multimodality management of patients with caval leiomyosarcoma: New treatment paradigms and potential molecular insights., PMID:33650695
Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma: a case report., PMID:33569329
Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas., PMID:33524869
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors., PMID:33474828
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma., PMID:33177152
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab., PMID:33147355
Angiosarcomas of Primary Gynecologic Origin - A Case Series and Review of the Literature., PMID:32988901
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report., PMID:32670543
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland., PMID:32391141
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial., PMID:32259228
Treatment for Advanced Soft Tissue Sarcoma: An Informative Neutral Trial., PMID:32259216
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas., PMID:32235164
Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?, PMID:32161464
Novel Aspects of Genetics, Molecular Biology and Clinical Oncology of Sarcomas., PMID:32075391
Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience., PMID:31996176
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma., PMID:31821732
Advances in soft-tissue sarcoma - There are no mistakes, only lessons to learn!, PMID:31807494
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab., PMID:31696433
Relevance of Anti-Galactose-α-1,3-Galactose Antibodies in the Era of Monoclonal Antibodies., PMID:31693451
Negative phase III trials announce the need for biomarkers in sarcoma., PMID:31675613
Revocation of the conditional marketing authorisation of a cancer medicine: The olaratumab experience., PMID:31655357
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria., PMID:31620878
Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour., PMID:31567307
A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma., PMID:31410509
Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts., PMID:31331295
Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?, PMID:31321082
The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model., PMID:31299622
Incidence and Management of Olaratumab Infusion-Related Reactions., PMID:31268811
Olaratumab failure in sarcomas: what are the lessons learned?, PMID:31254941
American Society of Clinical Oncology (ASCO) - 55th Annual Meeting (May 31-June 4, 2019 - Chicago, Illinois, USA)., PMID:31250844
ANNOUNCE prompts questions over the Accelerated Approval process., PMID:31249400
For research use only. Not for human or drug use.
